ClarityDX® technology can be used to predict the risk of disease.
The diagnosis and management of chronic diseases is a significant challenge and burden to healthcare systems globally.
At Nanostics, we predict the risk of diseases using our ClarityDX platform. This advanced technology combines Machine Learning with data from proprietary and/or non-proprietary biomarkers found in biofluids, such as blood or urine.
Our proprietary biomarkers, identified as crucial for disease prediction, are carried on extracellular vesicles (EVs). EVs are continuously released from cells and are in present in most biological fluids including blood, urine, semen, and cerebrospinal fluid. Nanostics uses microflow cytometry to quantify EV size, concentration, and marker abundance for millions of EVs in minutes.
Advanced machine learning algorithms analyze the combined biomarker and clinical data sets to provide rapid and precise results.
The ClarityDX platform is set to transform the screening landscape, making easy-to-use, minimally invasive predictive tests a reality.
